Qiming Venture Partners Portfolio Companies Axera, StepFun, Nasn Auto, Adagene, Infinigence AI, Galaxy Universal, and Zhipu AI Named to ChinaVenture 2024 Top 100 Rising Companies List
The list aims to identify the year's most innovative and fastest-growing technology companies.
Recently, the 2024 ChinaVenture Rising 100 list was officially released. The list aims to identify the year's most innovative and fastest-growing technology companies.
Qiming Venture Partners portfolio companies Axera, StepFun, Nasn Auto, Adagene, Infinigence AI, Galaxy Universal, and Zhipu AI were named to the list.
Axera, StepFun, Nasn Auto
Adagene, Infinigence AI
Galaxy Universal, Zhipu AI
Named to
2024 ChinaVenture Rising 100 List
- 2024 ChinaVenture Rising 100 List
ChinaVenture evaluated companies across three dimensions — external attention, industry synergy, and industry influence — through a process of open applications, surveys, market research, expert interviews, and data analysis to determine the final list.
This marks the fifth year that ChinaVenture has published the Rising 100 list. This year's list focuses on high-growth, actively funded companies in artificial intelligence, robotics, healthcare, and other technology innovation sectors, with "Rising" (锐, ruì) in the title. Rui means sharpness — from metal, with the sound of dui — naturally cutting, born to forge ahead, standing out in a world of infinite variety.
According to survey data and CVSource statistics, approximately 75% of listed companies are at pre-Series D funding stages, indicating that investors have placed substantial trust and support in high-growth-potential startups. Notably, some companies completed multiple funding rounds in less than a year, demonstrating strong capital market recognition, reflecting investor enthusiasm for quality assets, and injecting continuous vitality into China's technology industry.
Source | ChinaVenture
Past Coverage
Qiming Honors | Qiming Venture Partners and Portfolio Company Female Leaders Receive 10+ Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), APT Medical (688617.SH), Sanyou Medical (688085.SH), AmoyDx (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Caidya, Belief BioMed, Biren Technology, and others.